PGF2α stimulation of endometrial adenocarcinoma explants resulted in a significant increase in the expression of CXCL8 mRNA (Fig. 6C) and secretion of CXCL8 protein (Fig. 6D), which was inhibited by co-treatment of tissue explants with the specific FP receptor antagonist AL8810 (P < 0.001). The gene discussed is CXCL8; the disease is endometrium adenocarcinoma.